idarubicin , a more therapeutically effective derivative of daunomycin , when coupled to monoclonal antibodies that react with murine and human tumors has the ability to specifically target and eradicate tumor cell populations in vitro and in vivo .
C0020789
idarubicin
C0011015
daunomycin